JANSSEN GUSELKUMAB, TREMFYA (Janssen-Cilag Pty Ltd)
Product name
JANSSEN GUSELKUMAB, TREMFYA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
194 working days (255)
Active ingredients
guselkumab
Registration type
NCE/NBE
Indication
JANSSEN GUSELKUMAB and TREMFYA (solution for injection) is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.